Overall, METTL1 promotes HNSC malignancy by regulating global mRNA translation, including PI3K/AKT/mTOR pathway transcripts, while reshaping the tumor immune microenvironment, highlighting its potential as a therapeutic target. Here, METTL1 is linked to neoplasm.